The role of bone‐modifying agents in myeloma bone disease-Reference-Cited by-同舟云学术

The role of bone‐modifying agents in myeloma bone disease

Published:2021-06-15 Issue:8 Volume:5 Page:
ISSN:2473-4039
Container-title:JBMR Plus
language:en
Short-container-title:JBMR Plus

Author:

Lu Huifang¹^ORCID,Pundole Xerxes²,Lee Hans C.³

Affiliation:

1. Department of General Internal Medicine Section of Rheumatology and Clinical Immunology Houston Texas USA

2. Department of Health Services Research The University of Texas MD Anderson Cancer Center Houston Texas USA

3. Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center Houston Texas USA

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbm4.10518

Reference118 articles.

1. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Bone Disease in Multiple Myeloma: Pathophysiology and Management

3. Cancer Statistics, 2021

4. National Cancer Institute. Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Myeloma.2021.https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed May 29 2021.

5. Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography‐computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study;Moreau P;J Clin Oncol,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Use of Anti-Sclerostin Antibody in the Treatment of Multiple Myeloma: A Systematic Review;Journal of Pharmacy and Bioallied Sciences;2023-07

2. Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma;Journal of Clinical Medicine;2023-07-01

3. The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease;International Journal of Molecular Sciences;2023-03-03

4. The use of bone-modifying agents in multiple myeloma;Blood Reviews;2023-01

5. Biological and Clinical Aspects of Metastatic Spinal Tumors;Cancers;2022-09-22